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ABSTRACT 
 
Sickness behaviour refers to a set of coordinated behavioural and psychological changes in 
response to inflammation aimed to redirect available energy to the immune system to 
promote recovery. Sickness behaviour symptoms closely resemble important determinants of 
poor self-rated health, which in turn has been coupled to increased levels of inflammatory 
cytokines. However, it is not known if this association between inflammatory cytokines and 
self-rated health is mediated by sickness behaviour. Furthermore, it has not yet been 
established if other systemic and local inflammatory markers affect self-rated health, sickness 
behaviour and other patient reported outcome measures (PROMs). 
This thesis main aim was to investigate sickness behaviour as a determinant of self-rated 
health and as a possible mediator in an association between inflammatory markers and 
subjective health perception in primary care patients and in patients with asthma. 
In paper I, a questionnaire to measure sickness behaviour, SicknessQ, was developed and 
validated in two steps. First, sickness behaviour was experimentally induced by injecting 
endotoxin in healthy volunteers. The participants completed 37 items describing a broad 
range of sickness symptoms, items that responded to acute inflammatory provocation were 
selected and psychometric properties were tested in 172 primary care patients. The results 
demonstrated adequate psychometric properties for the resulting 10-item SicknessQ-scale and 
gave support for using SicknessQ as a brief instrument to assess human sickness behaviour. 
 
In paper II, the relationship between inflammatory markers, health anxiety, sickness 
behaviour and self-rated health was investigated in 311 primary care patients, 172 of which 
were also part of the study population in paper I. Furthermore, mediation analysis was 
conducted to exploratory investigate if putative relationships between inflammatory markers 
and self-rated health were statistically mediated by sickness behaviour. The results showed 
that poor self-rated health was associated with increased sickness behaviour and higher health 
anxiety. In addition, elevated levels of IL-6 were associated with poor self-rated health in 
men, although this association was not mediated by sickness behaviour. 
 
In paper III and IV, the longitudinal associations between self-rated health, sickness 
behaviour, asthma-related quality of life, inflammatory markers (paper III: FENO, ECP, 
EDN, IgE, paper IV: IL-5, IL-6) and lung function were investigated with repeated 
measurements in 181 patients with allergic asthma during 12-months. Poor self-rated health 
was associated with increased sickness behaviour, poorer asthma-related quality of life and 
high levels of seasonal IgE and food IgE but not total IgE or FENO, ECP or EDN. In men, a 
u-shaped relationship was found where both low and high levels of IL-6 were associated with 
increased sickness behaviour. Analysed over time, a worsening in sickness behaviour was 
associated with a worsening of self-rated health. Also, an improvement of asthma-related 
quality of life was associated with an improvement in self-rated health. In men, but not 
women, increased lung function measured as FEV1 was associated with an increase in IL-6, 
better self-rated health and increased asthma-related quality of life over the year. 
 
In this thesis, new knowledge is gathered to understand the underpinnings and interrelations 
between self-rated health, sickness behaviour and inflammation. More sickness behaviour 
emerged as a more consistent determinant of poor self-rated health compared to inflammatory 
markers, for which mixed results were found. The results of the thesis highlight the role of 
sickness behaviour in subjective health perception. 
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1 INTRODUCTION 
  
Diffuse sickness symptoms such as fatigue, malaise, depressed mood, fever and increased 
pain sensitivity are common and routinely treated in primary health care [1]. Due to their 
non-specific nature, these symptoms are sometimes found difficult to interpret and treat 
satisfactorily by the clinician. They represent a large cost for the society and most 
importantly, they impair the subjective health status for the individual. In fact, many of these 
diffuse symptoms are associated with poor self-rated health [2]. Poor self-rated health has 
been shown to be a predictor of morbidity and mortality in a number of studies [3-5] though 
relatively little is known about its biological and psychological determinants [6]. Several 
investigations show that measures obtained directly from the individual subject are strong 
predictors of mortality [3, 5]. The importance of self-ratings of health have increased lately 
with the inclusion of patient-reported outcomes in health care [7], but neither the biological 
underpinnings of perceived health nor why it is associated with objective health outcomes is 
well known. 
 
Inflammatory processes mediated by inflammatory cytokines are central to the pathogenesis 
of several maladies, for instance allergic asthma. Recently, the impact of inflammation on 
brain function has received much attention. Specifically, the brain has been shown to be 
partly regulated by peripheral signals such as inflammatory cytokines, which are central in 
orchestrating behavioural changes during acute inflammation by initiating a coordinated set 
of symptoms collectively referred to as sickness behaviour [8], including fatigue, pain and 
negative affect. Those symptoms closely resemble the main determinants of self-rated health 
which, in turn, are associated with poorer health [9], even when adjusted for diagnosis.  
 
Biological as well as behavioural aspects of sickness may be key to the understanding of 
diffuse and unspecific symptoms underlying many states of ill health that are often the 
reasons why a patient seeks primary health care. However, it is not known whether the 
association between self-rated health and inflammation is mediated by sickness behaviour or 
whether there are other independent contributors. Furthermore, it has not yet been established 
whether the inflammatory markers elevated in chronic inflammatory disease like allergic 
asthma may have an effect on subjective health appraisal. In addition, disease-specific 
markers such as those increased in allergic asthma in comparison to pro-inflammatory 
markers are less well characterised in terms of their influence on brain and behaviour. 
 
This thesis aims to investigate the importance of sickness behaviour for subjective health 
perception and if sickness behaviour mediates an association between inflammatory markers 
and subjective health perception in primary care patients and in patients with asthma. It was 
written in an effort to try deepen the knowledge of the underlying mechanisms behind diffuse 
symptoms of ill health with an ambition to ultimately be able to provide better care in the 
future for individuals who experience such symptoms. 
 2 
2 BACKGROUND 
2.1 PSYCHONEUROIMMUNOLOGY 
It is now well established that communication between the brain and the immune system is 
reciprocal [10]. Neuroendocrine and autonomic pathways are activated by behavioural 
responses to infectious stimuli resulting in modulation of the immune system [11]. The 
immune system is highly integrated with several other physiological systems. Its lymphoid 
organs are innervated by sympathetic, parasympathetic and sensory nerves and the immune 
system is able to interact with almost every hormone in the human body. Thus the immune, 
endocrine and nervous systems communicate bi-directionally and are not isolated closed 
circuits working independently of each other [12]. The field of psychoneuroimmunology 
therefore has emerged as an interdisciplinary effort to delineate the links between brain, 
behaviour and the immune system and provides one framework that can be applied for 
increased understanding of subjective health perception. 
 
As a short introduction to this interplay, the background section will be presented to explain a 
few basic principles of the immune system, the inflammatory process and how the immune 
system can communicate with the brain. This will be followed by a short background about 
self-rated health and sickness behaviour and finally, the chronic allergic inflammatory 
disorder asthma will serve as a model for investigating the influence of both local and 
systemic inflammatory factors on subjective health perception and sickness behaviour. 
 
2.2 THE IMMUNE SYSTEM 
 The immune system consists of an innate (non-specific) and an adaptive (specific) defence 
arm. Every day we encounter a number of threatening pathogens such as viruses and bacteria 
which are repelled by the innate immune system, acting as first line of defence. Usually this 
combat takes place without our knowledge and the threat is warded off before we even can 
detect any signs of infection. The innate immune system protects our bodies through a 
number of defences including anatomic, physiologic and inflammatory barriers and through 
cellular defence mechanisms. Furthermore, the innate and the adaptive immune systems 
closely interact with each other. The adaptive immune response can be further divided into 
cellular and humoral responses where the cell-mediated immune response is best suited for 
eliminating endogenous antigens (residing within the host) and the humoral response is more 
effective for eliminating exogenous antigens (produced outside of the host cell) [13]. In 
contrast to the fast acting innate response reacting within minutes to a few hours, the adaptive 
immunity reacts slower and develops within 1-2 weeks [14]. 
 
All white blood cells involved in the immune system are developed from a pluripotent stem 
cell into either lymphoid stem cells or myeloid stem cells [13]. The lymphoid stem cells can 
be further divided into B-lymphocytes, T-lymphocytes and NK-cells. The lymphocytes are 
the only cells in the immune system that possesses the immunological attributes of diversity, 
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self/non-self recognition, specificity and memory [15]. The myeloid stem cell is the 
progenitor of several cells in the innate immune system such as granulocytes (neutrophils, 
eosinophils and basophils), macrophages (such as microglia), dendritic cells and mast cells 
[14].  
 
2.2.1 The inflammatory response  
If the anatomic and physiologic barriers are not enough to protect the body from infection, 
the innate immune system will begin its action by recognition of pathogen associated 
molecular patterns, for example the endotoxin lipopolysaccharide (LPS) which is a 
component of gram negative bacterial walls. When the pathogen associated molecular 
patterns binds to pattern recognition receptors, a cascade of reactions will be induced 
including vascular and cellular changes in response to infection [15]. However, the 
inflammatory response can also occur in the absence of a pathogen in response to tissue 
injury for instance, and the inflammation is then classified as sterile inflammation [16]. 
 
Commonly when there is an infection or tissue damage, the immune system reacts by 
initiating a local inflammatory response. Local inflammation is characterised by five cardinal 
signs of inflammation: dolor (pain), calor (heat), rubor (redness), tumor (swelling) and 
functio laesa (loss of function). These changes are due to a complex series of events 
orchestrated by the immune system including increased production of cytokines by activated 
immune cells and cellular defence mechanisms [13]. If this reaction is insufficient in 
preventing further infection or tissue damage, the inflammatory process spreads further into 
the blood and creates a systemic inflammation which can eventually lead to sepsis and death 
if not cleared by the immune response [14, 17]. 
 
The granulocytic cells of the innate immune system react fast and neutrophils and eosinophils 
are generally the first arriving cells at a site for inflammation. They act through phagocytosis 
and by release of cytotoxic proteins. One of the cytotoxic proteins secreted by neutrophils is 
nitric oxide [18]. The eosinophils on the other hand secrete other cytotoxic proteins like 
eosinophilic cationic protein (ECP) and eosinophil-derived neurotoxin (EDN) [19-21]. The 
neutrophils are attracted by chemotactic factors such as IL (interleukin)-1  and IL-8, secreted 
from activated macrophages and a subset of T-cells called T-helper cells (TH) whereas the 
eosinophils are attracted by different chemokines and eosinophil chemotactic factor released 
by mast cells [14]. Macrophages arrive to the site of inflammation a few hours later after 
having circulated the bloodstream as monocytes. Before arriving, the monocytes enlarge and 
migrate from the blood vessels to the tissue where they differentiate into tissue specific 
macrophages [13]. At the site of inflammation, the macrophages act by phagocytosis, and 
similar to the neutrophils they secrete nitric oxide and other cytotoxic proteins [14]. In 
addition, they function as antigen-presenting cells to the adaptive immune system, and secret 
IL-6 which further promote B-cell differentiation and activate the humoral defence [22]. 
Macrophages also secrete tumor necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ) 
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which have cytotoxic effects and further activate macrophages and neutrophils, thus 
enhancing phagocytic activity even more. The system is thus able to facilitate and direct the 
response by suppressing or enhancing the production of a variety of interferons and cytokines 
[14]. After the initial combat, T helper  cells, T cytotoxic cells and B cells from the adaptive 
immune system arrive to provide help for driving and regulating the immune response [13]. 
The TH-cells can further be divided into TH1 and TH2 depending on their actions. TH1 cells 
secret cytokines such as IL-2 and IFN-γ, which activates cytotoxic T-cells and macrophages 
which act through the cell-mediated response suited for eliminating endogenous antigens. 
The TH2 cells secrete IL-6 and IL-10 which promote B-cells to differentiate into antibody 
producing plasma cells thus directing the humoral defence system towards fighting 
extracellular pathogens and mediating allergic reactions [14]. Some of the TH2 cytokines such 
as IL-4 and IL-5 induce production of immunoglobulin (Ig) E which is important in, for 
instance, allergic asthma [23].  
 
Inflammation can be divided into acute and chronic inflammation based on time course and 
immune response patterns. The acute inflammation transforms into a chronic state as a result 
of failure to eradicate or shut off the acute inflammatory trigger, autoimmune responses or 
chronic irritants [17]. In many chronic disorders the initiating trigger is not well defined and 
multiple triggers may be present. Resolution of inflammatory responses is terminated when 
adaptive inflammatory responses are terminated [14, 17].  
 
2.2.2 Immune system to brain communication 
Cytokines can be produced both peripherally and in the nervous system [14]. They are 
generally considered to be either pro-inflammatory or anti-inflammatory. Pro-inflammatory 
cytokines can induce one or several of the five cardinal signs of inflammation: fever (calor), 
pain (dolor), vasodilation (rubor), swelling (tumor) and loss of function (functio laesa) 
whereas the anti-inflammatory cytokines are involved in downregulation of the inflammatory 
cascade [13]. To be able to maintain a proper immune response, a well-regulated balance 
between pro-inflammatory and anti-inflammatory cytokines is crucial [24]. However, 
cytokines do not act one by one on their own but rather in cascades. Furthermore, the 
cytokines have redundant functions. During normal conditions cells encounter a milieu of 
various cytokines and cytokine actions are thus context-dependent [24-26]. 
 
Cytokines mediate specific physiologic responses in a similar manner to hormones and 
neurotransmitters by receptor-ligand interactions with self (autocrine), local (paracrine) and 
distal (endocrine) effects [27]. Cytokines can be produced by a large variety of cells. In 
addition, several unrelated cell types can produce the same cytokine. The primary source of 
cytokines is immune cells but some non-immune cells such as neurons and muscle cells can 
also produce cytokines [14]. Cytokines can be produced peripherally or in the brain [24].  
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Because the brain is involved in immune regulation, and behavioural changes are necessary 
to promote recuperation, the brain and the immune system need to communicate [24, 28]. 
Cytokines are too large to freely penetrate the blood-brain-barrier. Cytokines access the brain 
through a number of pathways. So far, five separate pathways have been described, see 
Haroon for a review [12]. Cytokines can enter the brain (1) through leaky regions in the 
blood-brain-barrier such as circumventricular organs, (2) through binding to cytokine specific 
transport molecules, (3) activation of cells lining the cerebral vasculature, or (4) by 
recruitment of activated monocytes and macrophages from the periphery to brain tissue 
which then initiates release of inflammatory mediators and cytokines directly into the brain. 
Peripheral cytokines can also (5) bind to cytokine receptors at afferent nerve fibres which 
innervate bodily sites. At sites of inflammation in the periphery, afferent nerve fibres become 
activated and transmit cytokine signals to specific brain nuclei such as the nucleus of the 
solitary tract. In the nucleus of the solitary tract the signals are then transmitted to other brain 
nuclei including the paraventricular nucleus in the hypothalamus [8, 12]. Thus, in response to 
peripheral cytokines activating afferent nerves, induction of expression of brain inflammatory 
cytokines takes place [27].  
 
In the brain, neurons and cells (such as microglia and astrocytes) express cytokine receptors, 
produce cytokines and amplify cytokine signals [13]. Microglia are the most active cytokine 
producing cells [29] and are the equivalent of macrophages in the brain. In response to 
peripheral inflammatory signalling, multiple cytokines such as IL-1β, TNFα, IL-6 and IFN-γ 
are expressed in the brain. Each of these cytokines also has the power to initiate or modulate 
neurochemical cascades that directly affect behaviour through the release of 
neurotransmitters including serotonin, dopamine, norepinephrine, monoamines and glutamate 
[12, 24]. In fact, this has been demonstrated by experimental acute or chronic administration 
of cytokines in numerous laboratory animal studies [30-32] and human studies [12, 26, 33]. 
Some of the resulting behavioural changes constitute a highly coordinated set of behavioural 
patterns referred to as sickness behaviour.  
 
The cerebrospinal fluid communicates with all cell types in the brain [12]. Cytokines 
produced in the brain can re-enter the blood circulation through resorption from the 
subarachnoidal space. They leave the brain through neuronal extensions of the 
subarachnoidal space that surround nerves going in and out of the brain and thus enter the 
peripheral blood [28]. Through the acute release of inflammatory cytokines influencing the 
brain the inflammatory response will have widespread effects on both the nervous system and 
the immune system. The immune system thus regulates behaviour and brain activity 
including emotional and cognitive domains [34, 35].  
 
2.3 SICKNESS BEHAVIOUR  
Sickness behaviour refers to a set of coordinated physiological and behavioural changes in 
response to systemic inflammation. These changes constitute an active process and are thus 
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not only passive consequences in response to inflammation. The behavioural pattern in the 
sickness response is referred to as sickness behaviour and typically manifests as fatigue, lack 
of energy, increased pain sensitivity, depressed mood, sleep changes, malaise, chills, anxiety, 
anorexia, psychomotor retardation, fever and anhedonia (i.e. inability to experience pleasure), 
figure 1 [28, 36, 37]. Several of these symptoms including fatigue, lack of energy, pain and 
depressed mood are the main determinants for self-rated health [38, 39] and the sickness 
symptoms thus closely resemble the determinants for self-rated health [9].  
 
The evolutionary biologist Paul Ewald theorised that host signs of infection could mainly 
function in three ways [40]. Firstly, host signs of infection could function to benefit the host. 
For instance, fever would be beneficial for survival of the host but not for the pathogen. 
Secondly, it could be of benefit for both the host and the pathogen. As an example, sneezing 
will help the host to get rid of the pathogen by exhaling both pathogen and mucus from the 
airways and at the same time it will help the pathogen to spread by aerosol to other hosts. 
Thirdly, it could benefit neither the host nor the pathogen. Ewald thus gave support to the 
idea that some behavioural patterns could be an adaptive response to fight infections. A 
couple of years after Ewald’s 1980 paper Hart published his study “ Biological basis of 
behaviour of sick animals” where he studied fever, a very energy intense state, in rats [41]. 
Hart argued that sickness behaviour could be understood as a coordinated response aiming at 
reducing costly energetic behaviour so that available energy could be redirected to raise the 
rats’ core temperature instead. He concluded that this behaviour was not a maladaptive effect 
of illness. Instead, this effort could be viewed as highly organised and evolved strategy to 
help in producing fever to combat infection. These studies have been followed by a long 
series of studies on sickness behaviour supporting the idea that these behaviours represent 
genetic adaptations to increase fitness and introducing the idea that dysregulation is a risk for 
illness in itself. Sickness response thus benefits the host, but can when unabated contribute to 
development of disorders such as depression [42]. 
 
Immune responses are highly energy dependent and increase resting expenditure [43]. Many 
of the sickness symptoms serve to limit motor and brain activity as well to limit appetite and 
thereby redirect metabolic energy to combat the primary infection or inflammation. Sickness 
behaviour such as motor inhibition and increased sleep helps conserve energy needed for 
recovery to increase the survival of the organism [41, 43, 44].  
 
Several studies have been conducted that support the notion that sickness behaviour is a 
motivational state. For instance, Aubert showed that female mice expressing sickness 
behaviour due to treatment with LPS (lipopolysaccharide, an endotoxin) diminished their nest 
building and pup retrieval compared to saline-treated controls [44]. The surrounding 
temperature was then decreased from normal 22° C to 6° C, threatening pup survival. 
Confronted with this threat, the LPS-treated mice ignored their sickness behaviour and 
increased their nest building and pup retrieval equalling the control animals [45]. In a study 
by Lasselin et al., healthy human subjects were injected with low-dose LPS to experimentally 
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induce sickness behaviour and then presented with a monetary reward task [46]. Despite the 
energy-saving behaviours expressed by the subjects, the incentive to receive a monetary 
reward altered the motivational state so that the task was carried out as long as the reward 
was considered to be worthwhile. The fact that sickness behaviour was suppressed when the 
evolutionary fitness was challenged contributed to the view of sickness behaviour as a 
motivational state, aimed at promoting recovery. Thus, sickness behaviour cannot simply be 
viewed as a sign of bodily weakness [42]. Besides experimental induction of sickness 
behaviour through administration of a pathogen it can be activated without involvement of a 
pathogen. For instance, sickness behaviour can be induced by conditioning [47] or by direct 
administration of LPS [48].  
 
On the one hand, behavioural changes following sickness behaviour facilitate recovery from 
an acute illness. On the other hand, these behavioural changes are believed to contribute to ill 
health when they persist long after recovery or where recovery has not been completed [49]. 
Over-exaggerated sickness behaviour can thus be damaging. This is particularly true in the 
case of chronic inflammatory diseases where persistent sickness behaviour leads to ill health. 
For example, a study showed that individuals with medical conditions such as rheumatic 
disease or certain forms of cancer experienced fatigue, depression or pain as a result of the 
inflammatory response triggered by the disease [50]. Other areas where longer-term effects of 
sickness behaviour have received growing attention are psychiatric illnesses such as 
depression [36, 51] and psychosis [52], other chronic inflammatory disorders [53] and 
cytokine cancer treatment [54].  
 
2.4 SELF-RATED HEALTH 
Subjective measures, such as self-rated health, obtained directly from the individual patient 
constitute one of the strongest predictors of mortality [3, 5], even when controlled for 
diseases and objective medical health issues [2, 5, 57]. In fact, self-rated health is often a 
better predictor of mortality and morbidity than objective health estimates and risk factors [5] 
and it is a stable and fairly reliable factor over time [58, 59]. The importance of self-ratings of 
health has increased recently with the inclusion of patient-reported outcomes in health care 
[7], but neither the biological underpinnings of perceived health nor why it is associated with 
objective health outcomes is well known [39, 60]. Self-rated health refers to an individual’s 
perception of his/her general health status assessed by using a single-item question, most 
often formulated as “How would you rate your general health status on a range from 
excellent to very poor?” It is, thus, the subjective view of one’s own health status rated on a 
specific scale and conducted by the individual instead of the clinician. In spite of being a one 
item question only, it captures a surprising amount of information [61]. A main reason for the 
relevance of self-rated health lies in its ability to predict future ill health and death [4, 5, 62] 
and the predictive value in relation to morbidity and mortality as well as other clinical 
outcomes brings up the need to clarify its biological basis. Lekander et al. have argued, and - 
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 Figure 1. Sickness behaviour typically manifests as fatigue, lack of energy, increased pain 
sensitivity, depressed mood, sleep changes, malaise, chills, anxiety, anorexia, psychomotor 
retardation, fever and anhedonia [28, 55, 56]. The term behaviour is here used in its wider 
sense, including emotion and cognition, in addition to overt behaviours/motor responses. The 
phenomenon was first observed in mice and other animals, then referring to observable 
responses.  
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presented evidence to support the idea, that the brain uses inflammation with its ensuing 
behavioural changes as a marker when health status is appraised [9, 63].  
 
An association between inflammatory cytokines and poor self-rated health has for instance 
been found in the elderly [64, 65], care-givers with age-matched controls [66] and women 
with cardiovascular disease [67]. High levels of IL-1β, IL-1ra and TNF-α have been 
associated with poor self-rated health in women but not in men (for which the number of 
participants was low) in a primary health care population [6, 9]. In fact, in the study by 
Lekander et al. self-rated health was found to be an independent and more robust predictor of 
those cytokine levels than physician-rated health [9]. Higher levels of IL-6 were associated 
with poorer self-rated health in older adults in ten consecutive measurements [68]. Other 
studies have shown different results. For instance, in one sample of 116 relatively younger 
healthy individuals aged 23-62, no association was found between the inflammatory 
cytokines TNF-α or IL-6 and self-rated health [69]. Self-rated health has also been associated 
with other markers of systemic inflammations, such as C-reactive protein [66, 70-72], 
increased fibrinogen [73] and higher erythrocyte sedimentation rate [74]. Finally, it should 
also be noted that the inflammatory marker that has shown a significant association with self-
rated health has varied somewhat across studies and results are thus not fully consistent in 
this respect. 
 
2.5 PROMS - SUBJECTIVE MEASURES OF HEALTH AND DISEASE 
When a clinician measures self-rated health or asthma-related quality of life no technical or 
expensive equipment is needed. Instead, these measures are reported directly by the patient 
without interpretation of the response by a clinician or anyone else. They are subjective 
measures of the patient’s perceived health which cannot be objectively verified. Collectively, 
such measures are called patient-reported outcomes (PROMs). PROMs can be divided into 
generic PROMS considering general aspects of health (such as self-rated health and sickness 
behaviour), or disease specific PROMs tailored to capture disease-specific symptoms and 
impact on function (such as asthma-related quality of life).  
 
PROMs have been indicated to increase cost-effectiveness and improve survival and are 
designed to capture the patients’ views of their symptoms, their functional status and their 
health-related quality of life [75-77]. They were initially developed for use in research, but 
have recently gained interest also in clinical practice since most clinicians have now started to 
recognise the benefits of incorporating the views of patients in their recorded assessment of 
the patient’s health status. The reliability of PROMs is similar to that of clinical measures 
such as blood glucose or blood pressure [78]. 
2.6 ASTHMA 
Most studies on sickness behaviour and self-rated health have so far been conducted on acute 
inflammatory conditions. Less is known about the relationship between sickness behaviour, 
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self-rated health and inflammatory markers during states of chronic inflammation. In this 
thesis, asthma was chosen as a representative model of chronic inflammatory disease with 
both local and systemic inflammation.  
 
Asthma is a chronic inflammatory respiratory disorder characterised by episodic and 
reversible airway obstruction and bronchial hyperresponsiveness. In the GINA guidelines 
(Global Initiative for Asthma), asthma is defined by “the history of respiratory symptoms 
such as wheeze, shortness of breath, chest tightness and cough that vary over time and in 
intensity, together with variable expiratory airflow limitation”[79]. The disease usually starts 
in childhood although it can present at any age. Up to 300 million people worldwide are 
affected by asthma [80]. Asthma is the most common chronic condition to affect children 
[74].  The prevalence is approximately 5-10% in western countries [81]. In the West Sweden 
asthma study, consisting of a random sample of thirty thousand individuals aged 16-75 years 
living in West Sweden, Lötvall et al. reported an 8.3% prevalence of physician-diagnosed 
asthma in Sweden [82]. In another study, Wändell et al. reported that asthma was ranked 
number 17 of the most common groups of diagnoses in primary care during 2011 in 
Stockholm County [83]. 
 
Asthma is considered to be a heterogeneous disease and the emerging view is that asthma 
should be considered as a syndrome rather than a single disease [80]. Asthma has 
traditionally been divided into two clinical forms: allergic and non-allergic asthma. In recent 
years, clinicians have started to realise that dividing asthma into only two clinical forms is 
oversimplification and several phenotypes based on demographic, clinical and/or 
pathophysiological characteristics have now been recognised [79, 80]. However, the old 
division into two phenotypes is still of clinical value in a primary care setting and will 
therefore be used in this context.  
 
The most common asthma phenotype is allergic asthma [79, 84]. In allergic asthma, the 
patients are IgE sensitised to an allergen and there is usually a clinical correlation between 
allergen exposure and symptoms [84]. These features are in contrast to non-allergic asthma 
phenotype which per definition has no IgE reactivity. Furthermore, patients with allergic 
asthma usually have higher levels of IgE compared to patients with non-allergic asthma and 
the onset of the disease is at a younger age [84]. The risk of developing asthma increases with 
multiple sensitisation to different allergen groups [85]. In addition, patients with allergic 
asthma have an increased prevalence of atopic dermatitis and up to 80% of the patients have 
concurrent allergic rhinoconjunctivitis [80, 86].  
 
2.6.1 Pathophysiology in allergic asthma  
Allergic asthma is characterised by TH2-driven inflammation with recruitment of both 
eosinophilic granulocytes and mast cells [87]. It is a chronic inflammatory disorder of the 
airways where TH2-cells produce IL-4, IL-5 and IL-13 [88]. This TH2-dominated cytokine 
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balance drives the allergic inflammation, including a  switch in antibody production from 
IgM to IgE, and is related to the clinical manifestation of asthma [89]. The hallmark of an 
allergic response is immediate hypersensitivity reactions mediated by IgE-antibodies attached 
to specific parts of the membrane of mast cells and basophils [90]. When a mast cell or 
basophil encounters an allergen, the allergen gets trapped by the IgE-molecule which is 
bound to the surface of the cell. The cross-linking of IgE-antibodies and the allergen triggers 
the cell to release its granular content such as histamine, ECP, EDN and other cytotoxic 
protein, resulting in an “early phase” allergic reaction [14]. The signs and symptoms of this 
reaction are dependent on where in the body the granular content is released. When it is 
released in the lungs it can cause asthma. Other locations can be in the skin causing atopic 
dermatitis or eczema, the nose (rhinitis) or the gut (food-allergic reactions) [14, 90]. The 
degranulation and liberation of cytotoxic proteins and cytokines initiate the “late phase” 
allergic reaction. In the “late phase” eosinophils and neutrophils are recruited and activated 
on inflammatory sites sensitive to allergens where they will contribute to disrupting the 
epithelial cells causing erythema and continued swelling [14]. Chronic inflammatory asthma 
results in airway hyperresponsiveness, increased mucus secretion and airway remodelling. 
These changes, in turn, lead to airway obstruction and reduced lung function [91].  
 
In addition to the systemic inflammation with production of IgE and cytokines, there is also a 
prominent local eosinophilic inflammation [91]. When local eosinophils are activated they 
release granular proteins such as eosinophil-derived neurotoxin (EDN) and eosinophil-
cationic protein (ECP) which act locally in the lungs but also contribute to the systemic 
inflammation [92]. Several studies have shown a correlation between eosinophilic activity in 
the lungs, plasma levels of EDN (p-EDN) and serum levels of ECP (s-ECP) [21, 93]. High s-
ECP and p-EDN have been suggested to reflect asthma activity and severity [92, 94, 95].  
The local eosinophilic inflammation in the airways is also reflected in the fraction of exhaled 
nitric oxide (FENO ) [96-98], which is increased in patients with allergic asthma [99, 100]. 
Nitric oxide is produced by a reaction involving nitric oxide synthase (NOS) enzymes. NOS 
exists in three different isoforms: inducible (iNOS), endothelial (eNOS) and neural nitric 
oxide synthase (nNOS) [101]. Pro-inflammatory TH-2 cytokines such as IL-4 and IL-13 
upregulate iNOS in the respiratory epithelium which results in increased FENO [102, 103]. 
For a long time FENO has been considered to be a reliable marker of eosinophilic airway-
inflammation. However, recent studies indicate that FENO actually is more representative of a 
TH2-driven inflammation in the local bronchial mucosa rather than a general eosinophilic 
inflammation [102]. Furthermore, both IgE-antibody titres and positive skin-prick tests 
indicate that the degree of IgE sensitisation correlates to levels of FENO [104-106]. 
 
2.6.2 General PROMs and inflammation in asthma 
Traditionally when a clinician has evaluated the health and quality of life of a patient with 
asthma the consultation has relied on clinical examination and objectively verified clinical 
asthma measures. Recently, many studies have shown a weak correlation between clinical 
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asthma measures and asthma-related quality of life, suggesting that quality of life cannot be 
inferred by clinical data only [107-109]. In light of this new knowledge, PROMs are gaining 
more clinical interest but the usage of general PROMs in asthma so far has still been limited 
to a few clinical studies.  
 
The role of self-rated health and sickness behaviour in asthma, and its relation to chronic 
inflammation, are largely unknown. Syk and co-workers showed in a population-based study 
including 5355 persons from Stockholm County that persons with a diagnosis of asthma 
reported poorer self-rated health than persons without asthma[110]. Furthermore, self-rated 
health was associated with asthma at least as strongly as quality of life. 
 
To the best of my knowledge there are no published studies where sickness behaviour has 
been investigated specifically in asthma. However, in a study by Sundbom et al. patients with 
asthma who reported presence of anxiety, depression and sleep disturbances had significantly 
lower asthma-related quality of life compared to a group of patients with asthma without 
those reported sickness symptoms [111]. Unfortunately neither self-rated health nor 
inflammatory markers were included in that study and only some aspects of sickness 
behaviour were among the investigated variables. The knowledge about the associations 
between sickness behaviour, self-rated health and the inflammatory markers IgE, ECP and 
EDN in patients with asthma is also limited and sparse and no studies have been published 
investigating the associations between either self-rated health or sickness behaviour in 
relationship to the inflammatory markers, IgE, ECP and EDN. However, ECP has been 
reported to correlate positively to subjective symptoms and objective measures of asthma 
activity in a young Swedish population, which in turn are believed to influence subjective 
health [112].  
 
The association between inflammatory cytokines and allergic asthma has been more 
thoroughly studied. Allergic asthma is, as noted, characterised by a TH2-dominated cytokine 
balance including the production of the inflammatory cytokines IL-4, IL-5 and IL-13 [88]. In 
addition, the pro-inflammatory cytokine IL-6 has been shown to be elevated in both serum 
and in bronchoalveolar lavage in asthmatic patients [113]. Serum levels of IL-6 have also 
been suggested to be an adequate measure of disease activity [114] and are also of importance 
in subjective health appraisal [64, 68]. The cytokines IL-1β and TNF-α have both been shown 
to be increased in asthma [115] and have both been associated with poor self-rated health [6, 
9] and shown to be able to induce sickness behaviour [116, 117] 
 
The relationship between FENO on the one hand and factors of relevance for subjective health 
on the other is another area where the knowledge is limited and conflicting results exist. For 
instance, one study reported no effect on FENO -levels during examination stress in asthmatic 
students but a small reduction in FENO -levels was observed in non-atopic students [118]. 
Other studies have reported associations between higher FENO -levels and negative affect, 
anxiety and acute stress [119-121]. 
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2.6.3 Asthma-related quality of life - a disease-specific PROM 
Asthma-related quality of life is a disease-specific PROM aimed to capture the perceived 
impact of asthma on a patient’s quality of life. The concept of quality of life has become an 
increasingly used measure in clinical research. There is no exact definition of which 
parameters should be included in this term but the constructs that have historically been 
covered in quality of life measures are: “health status (most often symptom levels), functional 
status (activity capabilities or impairments) and the patient’s perception of the impact of these 
impairments on the individual’s quality of life” [108]. Focusing on the importance of the 
individual’s perspective could attain a more complete description of the patient’s perceived 
situation. The individual’s assessment of quality of life could complement classical clinical 
outcome variables, which may only partly describe the burden of illness. In asthma, PROMs 
could thus potentially improve the clinician's assessment and treatment by including the 
patient’s perspective of the disease [7]. There are several instruments measuring asthma-
related quality of life [108]. All of the instruments are constructed to try to identify the 
problems that are most frequent and troublesome for the patient and to evaluate to what 
extent those problems affect daily life. This thesis will focus on one of these instrument called 
Mini-Asthma Quality of Life Questionnaire (mAQLQ) which is frequently used in clinical 
settings [122]. 
 
In contrast to the gap in knowledge regarding the associations between general PROMs and 
asthma, the association between the disease-specific PROM asthma-related quality of life and 
measures of subjective health is well established. For instance, asthma-related quality of life 
is closely associated with all items in the subjective Asthma-Control Test consisting of five 
items including subjective limitation of function, subjective dyspnea, subjective nocturnal 
symptoms, self-reported medication and subjective perception of asthma control [123-125]. 
Syk and co-workers conducted a large randomised controlled trial investigating whether a 
FENO-guided anti-inflammatory treatment algorithm could improve asthma-related quality 
of life [126]. The study was called the NOAK study and in this case NOAK was an 
abbreviation for “Optimization of the anti-inflammatory treatment of asthma through exhaled 
nitric oxide for increased asthma-related quality of life”, not to be confused with the more 
commonly used NOAK-abbreviation referring to “new oral anticoagulants”. The NOAK 
study included 187 primary care patients with asthma diagnosis (material from this study is 
also used in paper III and IV in my thesis). The results showed that although FENO-guided 
anti-inflammatory treatment improved asthma symptom control and reduced the exacerbation 
rate, asthma-related quality of life as measured by mAQLQ was not significantly affected. 
Data from this study were further analysed post hoc at baseline and after one year to 
investigate if optimisation with inhaled corticosteroids (ICS) and leukotriene-receptor 
antagonist (LTRA) according to either symptoms or FENO -levels would vary over one year 
when parameters such as asthma control questionnaire and levels of IgE were taken into 
account. In total, 158 patients with well-controlled asthma were included in the post hoc 
analysis. The results showed that a decrease in perennial, total and all specific IgE correlated 
significantly with a reduction in FENO -levels, improvements in asthma quality of life and 
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improved asthma control. Importantly, this study suggested that IgE could be reduced by 
LTRA and ICS and result in a clinically important effect on asthma control and asthma-
related quality of life [127].  
 
There are only a few studies where the relationship between asthma-related quality of life and 
inflammatory markers has been investigated. Sundbom et al. recently investigated variables 
with potential impact on asthma-related quality of life in patients in the MIDAS cohort 
consisting of 369 children and young adults (aged 12-35 years) with physician-diagnosed 
asthma [111]. The results showed that uncontrolled asthma as measured by low Asthma -
Control Test score was the main predictor for impaired asthma-related quality of life. 
However, no association was found between mAQLQ and blood eosinophil count, levels of 
FENO, total IgE, lung function as measured by forced expiratory volume during one second 
(FEV1) or bronchial hyperresponsiveness which all are indicators of asthma control. 
 
2.6.4 Coherency between subjective PROMs and objective measures of 
disease  
More traditionally, objective measures such as clinical variables have been the first choice 
when trying to assess the patient’s quality of life. However, objective measures do not 
include the patient’s view of his or her own health status. Among the common objective 
asthma measures is lung function which can be measured as FEV1 by spirometry. Other 
relevant objective measures can be obtained through reversibility testing after 
bronchodilation or by measuring fraction of exhaled nitric oxide. Even though the use of 
either subjective PROMs or objective measures aims to capture information of the patient’s 
health, the two types of information obtained often mismatch, suggesting that quality of life 
cannot be measured using clinical data only.   
 
In a study by Ehrs et al. of 77 primary health care patients with mild asthma, no correlations 
were found between asthma-related quality of life (measured by AQLQ) and clinical 
measures of asthma, such as lung function, reversibility to bronchodilation or levels of FENO 
[128]. Sundell et al. investigated the health-related quality of life in 159 adolescents with 
asthma and found no correlation between quality of life and FEV1 [129]. In another study 
conducted by Wechsler et al. 46 patients with asthma where randomly assigned double-
blindly to treatment with an albuterol inhaler, a placebo inhaler, sham acupuncture or no 
intervention [130]. The subjective patient-reported improvement was significant in all three 
of the intervention-groups when compared to the control group even though no objective 
improvement was found. Shingo et al. conducted a study where the correlation between 
airway obstruction and patient-reported outcomes in 1576 patients with asthma was 
investigated [131]. The results showed that FEV1 was only weakly correlated to physical 
dimensions of asthma-related quality of life such as daytime symptoms and “as needed” beta-
agonist use. Taken together, these studies by Ehrs, Sundell, Wechsler and Shingo suggest that 
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there is a discrepancy between objective clinical asthma measure and subjective health 
appraisal in asthma.  
 
2.7 SUMMARY OF THE BACKGROUND 
With this background, a theoretical framework has been introduced highlighting an existing 
link between behavioural factors such as subjective health, different sickness symptoms and 
inflammatory markers, underlining the critical role of bidirectional communication between 
the immune system and the nervous system. Even though some parts of this intricate system 
have started to be explored, more knowledge is especially needed in patient populations 
where symptoms of sickness and subjective health factors are common complaints, such as in 
primary health care. 
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3 AIMS 
 
The overall aim of this thesis was to investigate sickness behaviour as a determinant of self-
rated health and as a possible mediator in an association between inflammatory markers and 
subjective health perception in primary care patients and in patients with asthma. 
 
The specific aims of each paper were as follows: 
  
 I To validate the Sickness questionnaire (SicknessQ).  
 
 II To investigate the relationship between inflammatory markers, health anxiety, 
 sickness behaviour and self-rated health in primary care patients. Furthermore, 
 to investigate through exploratory analysis if putative relationships between 
 inflammatory markers and self-rated health were statistically mediated by 
 sickness behaviour. 
 
III To investigate sickness behaviour, FENO, s-ECP, p-EDN and IgE as 
 determinants for self-rated health in patients with chronic allergic asthma 
 followed over 12-months. 
 
IV To investigate IL-5, IL-6, FEV1, sickness behaviour and asthma-related 
 quality of life as determinants of self-rated health in patients with asthma. In 
 addition, to investigate the  co-variation over time between inflammatory 
 cytokines and subjective patient reported outcomes in relation to objective 
 clinical measures.
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4 METHODS 
 
4.1 PARTICIPANTS AND STUDY DESIGN 
Data from three separate studies are included in this thesis:  
1) “Endotoxin study” 
2) “SIA” (Self-rated health and Inflammation at Älvsjö primary health care centre)  
3) “NOAK” (Optimization of the anti-inflammatory treatment of asthma through exhaled 
nitric oxide for increased asthma-related quality of life). 
 
Paper I is based on the endotoxin and SIA studies, paper II is based on the SIA study and 
paper III and IV are based on the NOAK study. Descriptive information about participants 
and study design are given in table 1. 
 
 
Table 1. Descriptive overview of paper I-IV 
 Paper I Paper I, II Paper III Paper IV 
Study Endotoxin SIA NOAK 
participants healthy 
volunteers 
consecutive 
patients from a 
primary care 
centre 
Randomised primary care 
population with asthma-diagnosis 
n 52 311 181 
age 28.6 (20-47, SD 
7.1) 
51.0 (18-86, SD 
16.6) 
41.0 (18-64, SD 12.4) 
women 55.8% 65.3% 48.1% 
study type experimental cross-sectional one-year longitudinal 
PROMS SRH 
SicknessQ 
SRH 
SicknessQ 
SicknessQ4 
HAI 
SRH 
Sickness-
composite 
SRH 
Sickness-
composite 
mAQLQ 
Systemic 
inflammatory 
markers 
IL-6 
IL-8 
TNF-α 
IL-6 
IL-8 
TNF-α 
IgE 
ECP 
EDN 
IL-5 
IL-6 
Local 
inflammatory 
marker 
 FENO FENO  
Objective 
measure of 
disease 
   FEV1(% 
predicted) 
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4.1.1 Endotoxin study (paper I) 
In this experimental study, healthy participants were recruited by advertising at university 
areas in Stockholm. In total, 23 men and 29 women without physical or mental health 
problems were recruited. For inclusion, participants had to be non-smokers and without 
previous history of inflammatory or psychiatric disorders. C-reactive protein was assessed to 
exclude an ongoing infection on the experimental day. Apart from the presently included 
paper I, other results from the same data collection have been reported in three other 
publications [132-134]. 
 
4.1.2 SIA study (paper I and II) 
The SIA study was a cross-sectional study of primary health care seeking men and women 
attending Älvsjö primary health care centre located in an urban area in Stockholm County. A 
total of 311 patients were consecutively recruited from a drop-in clinic, serving patients with 
a wide range of acute medical problems. The study was conducted in a two-wave data 
collection during six consecutive weeks 2012 and six consecutive weeks 2013. During 2012, 
179 patients completed the study (response rate of 83%) and during the second data 
collection, 132 patients completed the study (response rate 68%). Medical consultations 
regarding annual health examinations, prescriptions for addictive drugs, chronic pain 
conditions and extensions of sick leave or other certificates were referred to booked 
appointments instead of the drop-in clinic and were automatically ineligible. Pregnant 
patients, patients under 18 years of age and patients not able to speak and read Swedish were 
excluded. 
 
4.1.3 NOAK study (paper III, IV) 
The NOAK study was a 12-month longitudinal study. In total 181 patients (87 women) aged 
18 to 64 years with physician-diagnosed allergic asthma and a confirmed IgE sensitisation to 
at least one airborne perennial allergen were recruited from 17 primary health care centres 
from November 2006 to March 2010. The health care centres were located in seven different 
county councils in central and southern Sweden. All participants were non-smokers since at 
least one year before inclusion and had a previous smoking history of maximum 10 pack-
years. In addition, all patients had been on a medication with inhalation corticosteroids (ICS) 
since at least 6 months before the inclusion. The participants were randomised into two 
groups. The groups differed in how the anti-inflammatory treatment, dose of ICS and LTRA 
(montelukast 10 mg daily), was adjusted. The anti-inflammatory treatment was adjusted on 
the basis of FENO in the FENO -guided treatment group (n=93). In the control group (n=88), 
treatment was adjusted based on symptoms according to routine clinical practice [121]. In the 
papers included in this thesis, however, both treatment groups were collapsed into one group 
and followed over the one-year period. In total, the participants visited the health care centre 
six times during the study period. 
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4.2 ASSESSMENTS 
The assessments investigated in this thesis can be divided into PROMs, inflammatory 
markers and an objective measure of disease. 
 
4.2.1 PROMs 
 
4.2.1.1 SRH 
Self-rated health was assessed in all four studies using the SRH-5 question ”How do you rate 
your general health status”[38]. The response alternatives were rated on a five point Likert 
scale with the response alternatives: Very good (1), Rather good (2), Neither good nor poor 
(3), Quite poor (4) and Poor (5).  
 
4.2.1.2 Sickness behaviour  
Three scales were used to assess sickness behaviour (1) the Sickness Questionnaire 
(SicknessQ), (2) SicknessQ4 and (3) a composite measure of sickness behaviour called 
Sickness-composite. The Sickness Questionnaire (SicknessQ), used in paper I and II, 
consisted of ten questions rated on a four point Likert scale (with a maximum score of 30 
points) [48]. In addition, a short form of SicknessQ called SicknessQ4 (with a maximum 
score of 12 points), consisting of four items from the original SicknessQ, was included in 
paper II.  The data collection which resulted in paper III and IV was conducted before the 
development and validation of SicknessQ and at that time no validated measure of sickness 
behaviour existed. Therefore, in paper III and IV, a composite scale called Sickness-
composite attempting to measure sickness behaviour was used instead. The Sickness-
composite consisted of weighted means of the answers to the following questions “How 
satisfied are you with your situation regarding the following aspects: 
energy/sleep/fitness/appetite and memory” ranging from “very poor” (1) to “excellent, could 
not be better” (7). However, the scale was inverted during analyses to facilitate interpretation 
so that higher score corresponded to a higher degree of sickness behaviour. The items in 
Sickness-composite were originally derived from the ”Gothenburg Quality of life 
Instrument”[135]. The Sickness-composite measure is a slightly modified version of a 
composite sickness scale used in an earlier study by our research group [6]. The separate 
items of each sickness scale and the internal consistency between the different scales are 
presented in table 2.  
 
4.2.1.3 Asthma-related quality of life 
Asthma-related quality of life was assessed using the Mini-Asthma Quality of Life 
Questionnaire (mAQLQ) [122], developed by Juniper. The mAQLQ is a short 15-item 
version of the original AQLQ [136] (consisting of 32 items), aimed to measure functional 
problems (physical, emotional, social and occupational) that are most troublesome to adults 
with asthma. The responses on each item were rated on a Likert scale ranging from “all of the 
time/ totally limited” (1) to “none of the time/ not at all limited” (7). 
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Table 2. The included measures of sickness behaviour 
 SicknessQ SicknessQ4 Sickness-composite 
 I want to keep still I want to keep still How satisfied are  
 My body feels sore My body feels sore you with your  
 I wish to be alone  situation regarding  
 I don’t wish to do 
anything at all 
 the following  
aspects: 
 I feel depressed I feel depressed -energy  
 I feel drained  -sleep  
 I feel nauseous I feel nauseous -memory  
 I feel shaky  -appetite  
 I feel tired  -fitness 
 I have a headache   
response alternatives disagree(0) - 
agree(3) 
disagree(0)-agree(3) very poor(1)-
excellent, could not 
be better(7) 
Internal consistency 
(Cronbach’s alpha)1 
.86 0.60 0.72 
Correlation with 
SicknessQ 
(Spearman’s rho) 1 
Reference 0.91, p<.001 -0.06, p=0.441 
Paper I, II II III, IV 
1 
SIA data used for analyses 
 
 
4.2.1.4 Health anxiety  
Health anxiety was measured using seven items from the 18-items “Short health anxiety 
inventory” [137]. The seven items included worries about their own health, awareness of 
bodily sensations or changes, relief when the doctors tells them there is nothing wrong, 
thoughts about having an illness they have heard about, concerns about what bodily 
sensations mean, feelings of being at risk for developing an illness and thoughts about 
whether to be able to enjoy life if having a serious illness. The items chosen included six 
items from the main section and one item from the negative consequences section. Items 
were rated from lowest rating of health anxiety (1) to highest rating of health anxiety (4). The 
internal consistency of the 7-item scale (Cronbach’s alpha) was 0.82 and the correlation 
(Spearman’s rho) between the original 18 items and the 7-item scale was 0.87 (p<.001).  
 
4.2.2 Inflammatory markers 
The systemic inflammatory markers included in this thesis were inflammatory cytokines, 
eosinophilic proteins and immunoglobulins. The local inflammatory marker was FENO. 
 
4.2.2.1 Cytokines 
In paper I and II, circulating levels of the cytokines IL-6, IL-8 and TNF-α were analysed from 
serum using Millipore’s MILLIPLEX multi-analyte profiling (MAP) high-sensitivity human 
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cytokine kit (Millipore Corporation, Billerica, MA, USA) according to the manufacturer’s 
instructions (paper I) or from plasma using high-sensitive enzyme-linked immunosorbent 
assay (Quantikine hs ELISA, R&D systems, Minneapolis, USA) (paper II). In paper IV, 
plasma levels of the circulating cytokines IL-5 and IL-6 were analysed using OLINK 
multiplex immunoassay (Olink Proteomics, Uppsala, Sweden). 
 
4.2.2.2 IgE, ECP, EDN 
In paper II and III, S-IgE and S-ECP were analysed in a Phadia 100 system with 
ImmunoCAP Phadiatop® (dog, cat, horse, birch, timothy, Dermatophagoides pteronyssinus, 
Dermatophagoides farinae, Cladosporium herbarum, mugwort) and ImmunoCAP fx5® 
(cow’s milk protein, egg white, peanut, soy, wheat, fish) reagents (Immunodiagnostics, 
ThermoFischer Scientific, Uppsala, Sweden). Specific IgE antibodies were grouped into three 
categories: perennial (cat, dog, horse, mite x 2, cladosporium), seasonal (birch, timothy, 
mugwort) and food (cow’s milk protein, egg white, peanut, soy, wheat, fish). Plasma samples 
for EDN were analysed in a sandwich-ELISA (Diagnostics Development, Uppsala, Sweden). 
 
4.2.2.3 FENO 
In paper III, FENO was measured according to standardised recommendation using NIOX 
MINO (Aerocrine AB, Solna, Sweden). The participant was asked to inhale to total lung 
capacity through the NIOX MINO followed by exhalation for 10 seconds at 50ml/sec 
(assisted by visual and auditory cues). Mean values from two successive measurements were 
used. FENO can be influenced by individual factors such as age, height and sex.  Olin et al. 
reported that individuals aged above 64 years had 40 percent higher levels of FENO than 
those aged 35-44 years [138]. In the general population, women have been shown to have 
significantly lower FENO -levels compared to men [139-141]. Several reasons for sex 
differences in FENO -levels exist. According to Jilma et al. women have lower levels of 
plasma nitrate and therefore lower production of endogenous nitric oxide [142]. In addition, 
women have a lower airway diffusing capacity for nitric oxide due to smaller surface area of 
the conductive airways in relation to body size compared to men [143]. Thus, all mean FENO 
-values (parts per billion) were therefore divided by predicted normal FENO -values in non-
atopic adult subjects adjusted for height and age. 
 
4.2.3 Objective measure of disease 
 
4.2.3.1 FEV1 
In paper IV, forced expiratory volume in one second (FEV1) was assessed through 
spirometry (Vitalograph, Spirotrac IV, Buckingham, England). Hedenström’s reference 
values were used to calculate percent of predicted FEV1 [144, 145].  
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5 ETHICAL APPROVALS 
 
All studies were approved by the regional ethics committee in Stockholm, Sweden. The dnr-
numbers for the approvals are listed below: 
Paper I: 2008/955-31, 2009/1273-32, 2010/1362-32, 2010/1829-32 and 2011/1851-31/1 
Paper II: 2011/1851-31/1, 2012/27-32, 2012/952-32 
Paper III and IV: 2006/185-31/1 
 
6 STATISTICAL METHODS 
 
For all included papers in this thesis, STATA® 11.0 or 14.0 (StataCorp LP, Texas, USA) was 
used for all statistical analyses and an α-level of 0.05 was used to test for significance.  
Below is a summary of the main statistical analyses used in the included papers.  
 
6.1 DESCRIPTIVE STATISTICS AND BACKGROUND VARIABLES 
Differences between genders were tested for all variables using Student’s t-test (normally 
distributed interval or ratio scale data) or Mann-Whitney U-test (non-normally distributed 
ordinal scale data) when applicable in all studies.  
 
The PROMs included in this thesis were assessed on ordinal scales. In most cases they were 
approximately normally distributed and thus, mean and standard deviation were used to 
describe the study group characteristics.  
 
Two separate approaches were used to handle gender. In paper III, an interaction term 
between gender and the independent variable was included in analyses. By using this 
approach, gender was treated as an effect modifier rather than as a confounder. In paper II 
and IV, the analyses were stratified for gender. All models were adjusted for age and BMI as 
being possible confounders. In paper I, gender was used as a criteria validity variable. 
 
6.2 MIXED EFFECT REGRESSION MODELS (PAPER I, II AND IV) 
Mixed effect regression models with participant identity as random effect were used for 
repeated measurements. These models were used for three types of questions. Firstly, to test 
for correlations when data consisted of repeated longitudinal measurements for the same 
individual by including identity as a random effect (paper III, IV). Secondly, to test if 
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variables would change over time by adding time as a dummy variable in the model (paper 
III, IV). Thirdly, to test the effect of treatment for an outcome by including treatment and 
time as one interaction term (paper I).  
 
6.3 PSYCHOMETRIC PROPERTIES (PAPER I) 
In the process of developing SicknessQ, potential items to be included in the final scale 
which were significantly affected by endotoxin with a α-level below 0.05 were further 
analysed regarding psychometric properties in the first wave of the SIA-material of primary 
care patients. Specifically, response rate, response distribution, variability and inter-
correlations were tested. Factor structure was then tested by principal component analysis and 
internal consistencies were measured by Cronbach’s alpha.  
 
Concurrent criteria validity refers to how well a comparison between the measure of interest 
and an outcome measured at the same time fits. As an example, negative affect is a symptom 
which is included in both sickness behaviour and in depression. If a patient reports a similar 
rating for an almost identical item regarding negative affect on both a depression scale and on 
the SicknessQ scale, the concurrent criteria validity is considered to be high. For the 
concurrent criteria validity analyses, bivariate relationships between the final set of items in 
SicknessQ, anxiety, depression and self-rated health as well as demographic variables were 
calculated using Pearson or linear regression.   
 
6.4 SPEARMAN’S CORRELATIONS (PAPER II, III, IV) 
Spearman’s rank correlation is a non-parametric test for correlation. The test was chosen 
since the variables were ordinal and data non-normally distributed.  Spearman’s correlations 
were used to calculate cross-sectional crude and partial correlations between different 
parameters.  
 
In paper III and IV, Spearman correlations were also used to correlate delta values between 
visit 1 and visit 5 to investigate if changes in inflammatory factors were associated with 
changes in PROMs and lung function. Spearman rank correlations were used because of the 
non-normal properties of the delta values.  
 
6.5 MEDIATION ANALYSIS (PAPER I, II) 
A Sobel-Goodman test was used to test indirect statistical effects of mediation [146]. This 
mediation analysis was based on a longitudinal regression framework to test sickness 
behaviour as a putative mediator of the effect of inflammatory cytokines on self-rated health. 
In the mediation models in paper II, elevated levels of inflammatory cytokines (x, causable 
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variable) are assumed to cause poor self-rated health (y, outcome variable). The effect of 
inflammatory cytokines (x) may be mediated by sickness behaviour (M, mediator, 
intervening variable). If the mediation is complete, x will no longer affect y after M has been 
controlled for. In more detail, the a-path (X to M), was the interaction effect of inflammatory 
cytokines on sickness behaviour. The b-path (M to Y) was the association between the 
putative mediator sickness behaviour and self-rated health controlled for inflammatory 
cytokines. The indirect mediated effect was calculated as the ab cross. The model is 
graphically illustrated in figure 2.  
 
 
 
Figure 2. Schematic model of the mediation analysis in paper II 
 
Mediation is a causal model where the mediator is assumed to cause the outcome, not vice 
versa. On a similar note, statistics can be used to evaluate a presumed mediation model but 
mediation is not defined statistically. A model such as the model used in paper II is further 
limited to provide evidence for causality since it was a cross-sectional study and the time 
criterion, was therefore not fulfilled [147]. To fulfil the time criterion, the exposure needs to 
be assessed before the mediator and the mediator needs to be assessed before the outcome.   
 
6.6 CUBIC SPLINE TEST (PAPER IV) 
In paper IV, a univariate cubic spline regression model with three degrees of freedom [148] 
was used to conduct an exploratory test for non-linearity in the associations between 
inflammatory cytokines and PROMs. This was done due to the fact that non-linear 
associations between inflammatory markers and self-rated health previously have been 
demonstrated [149]. As the associations between cytokines, self-rated health and sickness 
behaviour were found to be non-linear in the cubic spline regression analyses, IL-5 and IL-6 
were divided into quartiles and the lowest category was used as reference in the analyses. To 
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further explore if the found relationships in fact were u-shaped (i.e. if quartile 2 and 3 differed 
significantly from quartile 4), quartile 4 replaced quartile 1 as reference. 
 
6.7 Z-TRANSFORMATION (PAPER III, IV) 
Crude values of IgE, ECP, EDN and cytokines were z-transformed to facilitate interpretation 
of regression coefficients (b) (paper III, IV) in the mixed effect regression models, where b 
represents the change in the outcome variable per one standard deviation increment in the 
exposure variable. In paper I and II, Pearson’s and Spearman’s rank correlations, respectively 
were used and z-transformation were unnecessary.  
. 
6.8 BOOTSTRAPPING (PAPER I-IV) 
Due to the non-normal properties of the parameters included in the mediation analysis (paper 
I, II) and in the mixed effect regression models (paper I, III, IV) all p-values were estimated 
by bootstrap with 1000 repetitions [150]. The resampling procedure produces a distribution, 
in this case of the standard error and p-value, that is non-reliant on the assumption of normal 
distribution.  
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7 SUMMARY OF STUDIES I-IV 
 
7.1 PAPER I  
 
Background and objectives 
Sickness symptoms are common reasons for seeking in primary care. They impair the 
patient’s subjective health and can be problematic to diagnose. Yet, comprehensive methods 
to measure sickness behaviour in humans are lacking. The aim of paper I was to develop and 
validate the questionnaire SicknessQ.  
 
Method 
The SicknessQ was developed and validated in two steps: Firstly, the participants in the 
endotoxin study completed the initial form of the SicknessQ with 37 items covering a broad 
range of sickness behaviours. The participants had blood samples drawn at baseline, at peak 
inflammatory response 90 minutes after injection, and 270 min after injection and analysed 
for circulating levels of IL-6, IL-8 and TNF-α. Secondly, 13 items that responded to an acute 
inflammatory provocation compared to placebo were selected and the psychometric 
properties were tested on 172 patients from the first data collection in the SIA study.  
Results and conclusion 
A one-factor solution (Cronbach’s alpha=0.86) was indicated in the principal component 
analysis and a final 10-item questionnaire, SicknessQ, measuring sickness behaviour was 
presented. In the validation process, the scale correlated with self-rated health (β=0.28, 
p<0.001), a single item of feeling sick (β=0.55, p<0.001), depression (β=0.41, p<0.001) and 
anxiety (β=0.36, p<0.01). 
The results from paper I demonstrate adequate psychometric properties for the 10-item 
SicknessQ scale and lend support for using SicknessQ as a brief instrument of human 
sickness behaviour.  
 
7.2 PAPER II  
 
Background and objectives 
It is unclear if the previously described association between inflammatory cytokines and poor 
self-rated health is mediated by sickness behaviour.  Furthermore, disease conviction or fear 
of disease is a core feature of severe health anxiety [151], and thus the reason why health 
anxiety was hypothesised to be associated with poor self-rated health in this population of 
primary health care patients. Although this objective was originally intended to be presented 
in a separate paper, the relevance of health anxiety became apparent also for the relation 
between inflammation, sickness and self-rated health.  In paper II, the aim was to investigate 
the relationship between inflammatory markers, health anxiety, sickness behaviour and self-
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rated health in primary care patients. We also aimed to investigate through exploratory 
analysis if putative relationships between inflammatory markers and self-rated health were 
statistically mediated by sickness behaviour.  
 
Method 
In total, 311 patients seeking primary health care were consecutively recruited from the drop-
in clinic aimed for short consultations for patients with a wide range of medical problems. 
The participants had their FENO measured, blood drawn (analysed for IL-6, IL-8 and TNF-α) 
and completed questionnaires regarding self-rated health, sickness behaviour, health anxiety 
and background factors. Due to the development process of the SicknessQ, the 10-item 
version was available for the 179 patients from the first data collection only while 
SicknessQ4 was available for all participants. The reason was that the first preliminary 12-
item solution was later revised, overlapping with the final 10-item solution by four items. In 
the statistical analysis, health anxiety was added as a covariate in an exploratory analysis as 
confounding was suspected. 
 
Results and conclusion 
Poor self-rated health was associated with both increased sickness behaviour as well as higher 
health anxiety. In men, elevated levels of IL-6 were associated with poor self-rated health as 
expected (rho: 0.26, p=0.009). The mediation analysis showed that sickness behaviour did not 
mediate this relationship (20.8% mediation, p=0.79). In women, the opposite relation was 
observed between IL-6 and self-rated health (rho:-0.15; p=0.04). However, the association 
was weak and rendered non-significant when adjusted for health anxiety (rho:-0.08, p=0.31). 
In conclusion, the study presents mixed results regarding the relation between inflammatory 
markers and self-rated health and does not support sickness behaviour as a mediator of the 
association between IL-6 and self-rated health.  However, both sickness behaviour and health 
anxiety are suggested as behavioural determinants of self-rated health. 
 
7.3 PAPER III  
   
Background 
Asthma is a chronic inflammatory respiratory disorder with eosinophilic inflammation in the 
airways, increased FENO and elevated levels of IgE. Little is known about co-variation over 
time between subjective health outcomes and inflammation in patients with asthma as well as 
in the general population. The aim of this study was to investigate sickness behaviour, FENO, 
s-ECP, p-EDN and IgE as determinants for self-rated health in patients with chronic allergic 
asthma.  
 
Method 
The relationship between local and systemic inflammatory parameters, self-rated health and 
sickness behaviour was investigated in 181 men and women with asthma over a 12-month 
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period during repeated measurements. The participants were randomised into two groups 
where the anti-inflammatory treatment was adjusted based on either the basis of FENO or 
adjusted based on symptoms. As there were no significant effect of treatment (inhaled 
corticosteroids  and leukotriene-receptor antagonist on self-rated health, sickness behaviour 
nor any of the IgE-variables, s-ECP, p-EDN, groups were combined in all analyses in this 
present report and treatment was included in the analyses as a possible confounder.  
  
Results and conclusion 
Poor self-rated health was associated with high levels of food IgE and seasonal IgE, but not 
total IgE, ECP, EDN or FENO. Furthermore, an increase over one-year in perennial IgE was 
associated with a worsening of self-rated health. Poor self-rated health was associated with 
more pronounced sickness behaviour. A worsening over the year in sickness behaviour was 
associated with a worsening of self-rated health. Sickness behaviour and self-rated health co-
varied over a one-year period, showing that sickness behaviour is a determinant of self-rated 
health in a group of patients with asthma. Future studies are needed to investigate the 
importance of specific IgE for perceived health.  
 
7.4 PAPER IV 
 
Background 
In addition to the eosinophilic inflammation, increased levels of FENO and IgE, asthma is 
also associated with increased plasma cytokines, reduced lung function and poor quality of 
life. The aim of paper IV was to investigate IL-5, IL-6, FEV1, sickness behaviour and 
asthma-related quality of life as determinants of self-rated health. In addition, to investigate 
the longitudinal co-variation over time between inflammatory cytokines and subjective 
patient reported outcomes in relation to objective clinical measures. 
 
Methods 
Self-rated health, sickness behaviour, IL-5, IL-6, quality of life and FEV1 were assessed in 
181 patients with allergic asthma with repeated measurements in a one-year longitudinal 
study. Similar to paper III, treatment groups were combined in all analyses in this present 
report and treatment was included in the analyses as a possible confounder.  
 
Results and conclusion 
More sickness behaviour and poorer asthma-related quality of life were associated with 
poorer self-rated health as hypothesised. In men, a u-shaped relationship was found where 
both low and high levels of IL-6 were associated with increased sickness behaviour. In 
addition, poor lung function was also associated with poor self-rated health. Over the year, 
improved asthma-related quality of life was associated with better self-rated health. Also, if 
sickness behaviour decreased, self-rated health improved, but only in women. In men, 
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increased FEV1 over the year was associated with an increase in IL-6, better self-rated health 
and improved asthma-related quality of life. 
 
8 DISCUSSION 
 
In this thesis, the associations between self-rated health, sickness behaviour, inflammatory 
markers and other PROMs as well as objective measures of disease have been investigated in 
both cross-sectional and longitudinal studies in healthy participants with experimentally 
induced sickness behaviour, primary care patients and patients with allergic asthma. In 
particular, an effort has been made to elucidate the role of sickness behaviour in the 
associations between inflammation and self-rated health. A global measure of sickness 
behaviour, SicknessQ, was developed and validated and was indicated to be an adequate 
instrument to measure subjective human sickness behaviour. 
 
8.1 MAIN FINDINGS 
8.1.1 Overall associations 
The main finding among the overall associations was that poor self-rated health was 
associated with increased sickness behaviour (Paper II, III and IV). This association was valid 
regardless of whether SicknessQ, the short form SicknessQ4 or the Sickness-composite 
variable was used as a measure of sickness behaviour. Furthermore, poor self-rated health 
was associated with other PROMs such as poor asthma-related quality of life (paper IV) and 
increased health anxiety (paper II). Thus, in accordance with our hypothesis, sickness 
behaviour and asthma-related quality of life were determinants of self-rated health in both 
primary care populations (paper I, II) and in patients with allergic asthma (III, IV). 
 
In addition to investigating the associations between subjective ratings of relevance for health 
and sickness, one of the main aims with this thesis was to delineate how these measures were 
related to inflammatory markers, such as cytokines (IL-5, IL-6, IL-8 and TNF-α) and other 
systemic or local measures of inflammation (IgE, ECP, EDN and FENO). The results showed 
that poor self-rated health was associated with increased levels of IL-8 (paper I), TNF-α 
(paper I), IL-6 (paper I, II), but not with IL-5 (paper (IV), in both women and men. 
Surprisingly, among the male population in paper IV, we also found that both low and high 
levels of IL-6 were associated with increased sickness behaviour in a u-formed fashion, a 
similar pattern was seen regarding self-rated health in men where the third quartile reported 
significantly better self-rated health than quartile one although no significant difference from 
quartile 4 was found. A non-linear relationship between IL-1β and long-term potentiation of 
the memory in rats has previously been indicated [34], perhaps suggesting that the 
involvement of e.g. IL-1β in basic physiological processes makes either too low or too high 
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levels coupled to sub-optimal functioning and thereby subjective health appraisals. More 
studies are needed in order to delineate if there is a similar non-linear relationship between 
IL-6 and sickness behaviour. There were no u-shaped association between levels of IL-6 
and self-rated health. Poor self-rated health was further associated with an increase in the 
inflammatory markers seasonal IgE and food IgE in both men and women (paper III). 
However, the inflammatory markers ECP, EDN or FENO were neither related to poor self-
rated health nor sickness behaviour (paper III).  
 
One possibility why increased seasonal IgE and food IgE was associated with poor self-rated 
health is that patients who have to occasionally worry acutely about having an allergic 
reaction to allergens they encounter when they eat something unfamiliar or when they are 
exposed for a seasonal allergen would experience poorer health compared to patients having 
allergic reactions to perennial allergens that are present at all times during the year. It is 
possible that the latter group of patients have adapted to the constant danger of having an 
allergic reaction in a similar fashion as described during a “response shift”. A “response 
shift” refers to when patients have adapted to their disease to such extent where they rate their 
health as good as before the onset of disease despite the presence of their disease [152-154]. 
Thus, patients with perennial allergy exposure might rate their health higher than those who 
occasionally experience fear of an acute allergic reaction and the relationship between levels 
of IgE and subjective health could potentially have a clinical importance. However, more 
studies are needed to investigate and further delineate the relationship between IgE, other 
inflammatory markers and subjective health perception. More specific, it would be interesting 
to conduct a study to investigate if there are any differences in self-rated health between 
patients with seasonal or perennial allergy.  
 
In study IV, FEV1 was used as an objective measure of lung function in patients with asthma. 
In men, but not in women, improved FEV1 over one year was associated with better self-
rated health, decreased sickness behaviour and increased asthma-related quality of life. No 
correlation was found between FEV1 and any of the PROMs in women. The phenomenon of 
discrepancy between PROMs and objective clinical asthma measures are well known and 
described in a number of studies [128, 130] Even so, FEV1 was one of the strongest physical 
predictors, and self-rated health the very strongest predictor (at least in men), of all-cause 
mortality in a large study of almost 500 000 UK Biobank participants [3]. Apparently, how 
subjective ratings relate to objective measures is an area still in its infancy, and I hope that 
small steps such as those taken in the present thesis can contribute to its gradual development. 
The obvious importance of outcomes such as morbidity and mortality and the way they are 
related both to self-ratings and more biomedical measures warrants further research. For 
example, how much can biomedical measures complement self-ratings of health to inform 
about the patient's health status, and are the relations between self-rated health and mortality 
due to a "true" evaluation of bodily state or rather reflecting the fact that self-rated health 
influence behaviours that in turn influences mortality rates? There is in fact support for both 
these and related explanations [4, 57], and future research needs to combine observational 
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and experimental approaches to understand the underpinnings of self-rated health and why it 
is connected to future objective health.  
 
8.1.2 Longitudinal covariations 
Both paper III and IV were bases on a longitudinal data collection conducted to investigate if 
and how the parameters co-varied over one year. In these longitudinal studies, increased 
sickness behaviour was associated with deterioration in self-rated health in both men and 
women (paper III) while this association was significant in women only in gender stratified 
analyses (paper IV). These results are new and give important information and may have 
reflected a causal relationship between increased sickness behaviour and poor self-rated 
health.  
 
Increased levels of perennial IgE were associated with poorer self-rated health over the year. 
There were no longitudinal covariations between any of the PROMs and the other 
inflammatory markers (cytokines, ECP, EDN or FENO) in paper III and IV. This lack of 
covariation between PROMs and the remaining inflammatory markers could be due to 
several reasons, apart from being a true negative finding. First, the participants rated their 
health as “quite good” already at the start of the study which decreases the variation in the 
invested variables since the room for improvement is limited. Secondly, it is possible that 
inflammatory markers fluctuate more rapidly than is relevant for the subjective ratings. This 
would be congruent with some previous data where a link between self-rated health was 
concluded to have a trait- like component in addition to a relationship over very short time 
scales (hours to days) that has been demonstrated  in experimental studies [68].  
 
8.1.3 Mediation analyses  
Analyses of statistical indirect effects of mediation were conducted in paper I and paper II. In 
paper I, all three cytokines (IL-6, IL-8 and TNF-α) were significant mediators of the 
experimentally induced effect of endotoxin on SicknessQ. In paper II, sickness behaviour was 
not indicated to mediate the association between increased levels of IL-6 and poor self-rated 
health in men in primary care. The direction of causation – if present at all – should be 
interpreted with caution, especially as the data in paper II were cross-sectional. For this and 
other reasons, more longitudinal studies are needed in order to try to better elucidate both the 
relation over time between inflammatory mediators and self-rated health and the putative role 
of sickness behaviour in this relation.   
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8.2 METHODOLOGICAL CONSIDERATIONS 
8.2.1 Three ways of measuring sickness behaviour 
One limitation in this thesis is that three separate measures have been used in an effort to 
measure human sickness behaviour in an adequate fashion. In paper III and IV, a Sickness-
Composite scale was used since no validated measure of sickness behaviour existed when the 
study was planned. In paper I, a global measure of sickness behaviour was constructed and 
validated, suggesting a one-factor solution as indicated by a principal component analysis. 
This global measure of sickness behaviour, called SicknessQ, and a short form of SicknessQ 
(SicknessQ4) were used in paper II. The separate items of each sickness scale and the internal 
consistency between the different scales are presented in table 2. The association between 
SicknessQ and SicknessQ4 was satisfactory (Spearman’s rho=0.91. Thus, the results suggest 
that the short form SicknessQ4 can be used as an alternative to SicknessQ. However, the 
association with the Sickness-Composite scale was low (Spearman’s rho=.14) and is not 
interchangeable for SicknessQ or SicknessQ4. 
 
The major difference between the SicknessQ, SicknessQ4 and Sickness-composite scale is 
that items associated with pain, depression, positive or negative affect are lacking in the 
Sickness-composite scale. Contentwise, this is a clear and obvious limitation since pain, 
depression, positive or negative affect have been shown to be of importance when measuring 
sickness behaviour [48, 149, 155, 156]. In paper I and II including a wide range of patients 
from primary care, muscle and joint pain was the reason for seeking medical care in 17% of 
the patients and 8.7% were seeking care for depression. Thus, a measure of sickness 
behaviour such as SicknessQ or SicknessQ4 which includes pain, depressive mood and affect 
would probably be more accurate to use not only in the primary care population but also in 
patients with asthma. 
 
8.2.2 Measuring inflammation off-site from the region of interest 
In this thesis, inflammatory markers were measured either in peripheral blood or in exhaled 
air. Measuring nitric oxide in exhaled air can be considered to be a reasonable approach to 
measure local airway inflammation since eosinophilic airway inflammation has proven to be 
reflected in FENO. Considering IgE, ECP and EDN, the highest concentration of those 
proteins would be located at the site of inflammation. In the case of allergic asthma, the 
highest concentration of inflammatory proteins supposedly would be located in the airways 
even though asthma has also proven to be a systemic inflammatory disorder [157]. Still, IgE, 
ECP and EDN were measured in peripheral blood. The same scenario was true for 
inflammatory cytokines. Circulating cytokines were measured in peripheral blood instead of 
cerebrospinal fluid. It should make sense to measure cytokines in cerebrospinal fluid by 
lumbar puncture since it is located on the inside of the blood-brain barrier and therefore in 
close proximity to the brain which has the capability to induce behavioural changes. The 
approach of measuring levels of circulating cytokines in peripheral blood was chosen 
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although knowledge about the exact relationships between differences in local and systemic 
concentrations of cytokines, interactions and impact on behaviour are still are partly 
unknown. However, even though the cytokines are measured from a distance from the brain 
which would appear to be the logical place to measure cytokines if trying to study the 
relationship between cytokines and behaviour, it is now well known that cytokines can enter 
the brain through several pathways [12-14]. For instance, afferent nerve fibres in the 
periphery transmit cytokine signals to specific nuclei in the brain and peripheral cytokines 
circulating in the blood during a systemic inflammation are thus able to communicate directly 
with the brain [12]. In this thesis, lumbar puncture was not conducted due to practical and 
patient safety reasons. Instead circulating cytokines as well as IgE, EDN and ECP were 
measured in peripheral blood based on the idea that these markers would act as proxies 
having a putative impact on behaviour although these peripheral markers would not be a 
perfect reflection of the situation inside the blood-brain barrier. The approach measuring 
inflammatory markers off-site from the region of interest has gained support in many studies 
and proven to be adequate in several settings such as in paper I and other studies where strong 
associations have been shown between circulating cytokines and behavioural changes due to 
injected endotoxin [48, 158, 159].  
 
8.3 STRENGTHS AND LIMITATIONS 
This thesis has several strengths. The main strengths include that the patient samples in the 
SIA and NOAK studies were, by and large, representative for patients treated in primary care 
regarding study group characteristics (paper II,III, IV),  reasons for seeking medical care 
(paper II) and degree of asthma severity i.e. mild to moderate asthma (paper III, IV) [83]. In 
addition, both experimental and longitudinal designs were applied. The experimental 
approach used in paper I belongs to a fast-growing tradition, where stimuli like LPS (as in the 
endotoxin study in paper I), or, among other examples, typhoid vaccines [35] are commonly 
used. Studies of health trajectories in relation to inflammatory markers are still scarce, and 
hopefully, this this thesis can contribute to the knowledge base within this part of 
psychoneuroimmunology.  
 
One limitation, as mentioned above, is the fact that the SicknessQ-scale was not developed at 
the starting point of the NOAK study (paper III, IV) and could therefore not be used 
consistently through this thesis. Another limitation is that analyses needed to be cross-
sectional in study I, why studies of temporal relations, could not be studied. Finally, on 
average the participants in the included studies rated their initial health between “rather good” 
and “neither good nor poor”, thus somewhat limiting the range of variability in the 
investigated parameters. Despite the fact that a limited variability in self-rated health narrows 
the possibility to report eye-raising results, as a clinician you cannot really be unhappy about 
the fact that the majority of your patients actually rate their health on the positive half of the 
scale. 
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8.4 FUTURE CLINICAL PERSPECTIVE  
In this thesis the associations between inflammatory markers and self-rated health show 
mixed results and the importance of inflammatory markers for self-rated health, sickness 
behaviour and other PROMs needs further investigation. However, we know from previous 
research that poor self-rated health is often the best and most robust predictor of future 
morbidity and mortality [3, 4, 62]. Still, during regular clinical practice, most Swedish GPs 
find themselves routinely ordering blood samples and tests, but seldom routinely ask the 
patient the simple question “How do you rate your health status?” or use other PROMs 
during the consultation. More and more evidence highlights the importance of incorporating 
the patient’s subjective health during the clinical consultation. Personally, I believe that 
incorporating the patient’s view of their health should be a matter of course. Not only should 
it be viewed as a valuable complement during the consultation, but as a way of getting 
information that cannot be obtained by objective clinical measures. 
 
8.5 CONCLUSION 
This thesis adds new knowledge about the role of sickness behaviour in the relation between 
inflammation and subjective health perception. The questionnaire SicknessQ was developed 
and validated as a measure of human sickness behaviour. Sickness behaviour was shown to 
be associated with inflammatory markers both in experimental and cross sectional settings. 
Health anxiety is suggested as a relevant factor to be considered in the study of determinants 
of self-rated health. Furthermore, the results suggest that both sickness behaviour and asthma-
related quality of life are determinants of self-rated health by showing that these factors co-
vary over a one-year period in patients with allergic asthma. However, sickness behaviour 
was not found to be a mediator in the association between inflammatory markers and self-
rated health. High levels of IL-6 were associated with poor self-rated health in men, both in 
primary care center patients and patients with asthma, otherwise the association between 
inflammatory cytokines and self-rated health showed mixed results. The importance of IgE 
for perceived health in patients with asthma needs further investigation. 
 
8.6 CONCLUDING REMARKS 
As a note of caution, it is important to be aware of the limitations in trying to condense the 
highly complex processes intertwining human sickness behaviour, subjective health and 
inflammation into a few statistical calculations and assumptions, notably based on only a few 
sampling occasions for each participant. In light of scientific history, I think it is important to 
keep an open mind and remember that the current view will probably be substantially 
modified and differentiated during the years to come. Even though many great (and some less 
significant) discoveries have been made so far in psychoneuroimmunology, we have 
probably only started to scratch the surface of this interesting field. 
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9 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Ospecifika diffusa sjukdomssymtom som trötthet, sjukdomskänsla och energibrist är vanliga 
orsaker till att patienter uppsöker primärvården. Dessa symtom orsakar ofta patienten stort 
lidande och är på grund av sin ospecifika natur ibland svåra för läkaren att tolka och 
behandla. Flera av dessa ospecifika symtom förknippas med låg självskattad hälsa. 
Självskattad hälsa är patientens egna svar på frågan ”Hur bedömer du ditt allmänna 
hälsotillstånd?” där läkarens tolkning inte ingår. Faktum är att det som allra bäst visat sig 
förutsäga patients framtida sjuklighet och död i många fall varit patients egen självskattade 
hälsa. Patienters subjektiva hälsobedömningar av olika tillstånd och symtom brukar med ett 
sammanfattande begrepp kallas för patientrapporterade utfallsmått och förkortas på engelska 
till PROMs. Man har i flera studier visat att flera PROMs, och däribland särskilt självskattad 
hälsa, till och med ger bättre mått på framtida sjuklighet och död än vad läkarens bedömning, 
provsvar och undersökningar kan ge. Man känner dock inte till den biologiska bakgrunden till 
detta samband.  
Inflammatoriska processer ingår som en del i många sjukdomar som t.ex. infektioner, cancer, 
depression, fetma och astma. Under de senaste åren har mycket forskning inriktats på att 
förstå hur hjärnan påverkas av inflammatoriska signaler. Man har funnit att en grupp 
inflammatoriska proteiner som kallas cytokiner kan signalera till hjärnan. När hjärnan får 
dessa signaler kan den starta ett särskilt program med beteendeförändringar som med ett 
gemensamt begrepp kallas för sjukdomsbeteende. I sjukdomsbeteendet ingår att vi helst vill 
ligga stilla och vila, vi känner oss trötta och sjuka, får en ökad smärtkänslighet och vill inte 
roa oss eller äta. Genom att bete oss på detta sätt när vi har förhöjd inflammatorisk aktivitet 
undviker vi energikrävande beteenden och istället skapas förutsättningar för vila. Vi 
omdirigerar därigenom vår energi till det energikrävande immunsystemet så att det kan arbeta 
för att göra kroppen frisk igen. Sjukdomsbeteende fyller alltså en funktion vid akuta 
inflammatoriska sjukdomstillstånd, men tros kunna vara till skada om sjukdomsbeteendet 
fortsätter när den akuta inflammationen har läkt ut eller om inflammationen blir kronisk som 
t.ex. vid astma. Intressant nog påminner de symtom som ingår i sjukdomsbeteendet mycket 
starkt om de faktorer som gör att vi skattar vår hälsa som dålig. Genom att undersöka de 
biologiska och beteendemässiga effekterna av sjukdomsbeteende skulle man kunna få ökad 
kunskap om diffusa och ospecifika sjukdomssymtom och på sikt förhoppningsvis kunna ge 
patienter med dessa symtom bättre vård och behandling.  
Syftet med denna avhandling var dels att undersöka hur sjukdomsbeteende påverkar den 
subjektiva hälsouppfattningen och dels att ta reda på om ett samband mellan inflammation 
och subjektiv hälsouppfattning förmedlas av sjukdomsbeteende (d.v.s. att inflammation ger 
upphov till sjukdomsbeteende som i sin tur påverkar hur man skattar sin hälsa) hos patienter i 
primärvården och hos patienter med en kronisk inflammatorisk sjukdom som astma.  
I artikel I utvecklade och validerade vi ett frågeformulär för att mäta sjukdomsbeteende. Först 
fick friska försökspersoner en injektion med lågdos av bakteriedelar (s.k. lipopolysaccarid, 
LPS) eller placebo för att inducera ett kortvarigt experimentellt sjukdomsbeteende. Därefter 
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fick de lämna blodprov för inflammatoriska cytokiner och fylla i frågeformulär med frågor 
om sjukdomsbeteende och symtom. Vissa frågor och påståenden, som t.ex. ”jag känner mig 
trött” besvarades olika beroende på om deltagaren tillhörde gruppen som fått bakteriedelar 
eller placebo vid experimentet. De frågor där svaren skiljde sig åt mellan grupperna valdes ut 
och testades sedan på 179 patienter som sökt akut på vårdcentralens drop-in mottagning. 
Efter flera statistiska test av frågornas egenskaper valdes 10 frågor ut till frågeformuläret. 
Slutresultatet blev ett konstruerat och validerat frågeformulär, SicknessQ, som visade sig vara 
ett adekvat formulär för att mäta sjukdomsbeteende.  
I artikel II undersöktes sambandet mellan inflammatoriska markörer (utandad kvävemonoxid 
och cytokinerna IL-6, IL-8 och TNF-α), hälsoångest, sjukdomsbeteende och självskattad 
hälsa hos 311 primärvårdspatienter. Dessutom undersöktes om ett eventuellt samband mellan 
inflammatoriska markörer och självskattad hälsa förmedlades av sjukdomsbeteende. 
Resultaten visade att låg självskattad hälsa hade ett samband med ökat sjukdomsbeteende och 
mer hälsoångest. Hos männen, men inte hos kvinnorna, fann vi ett samband mellan höga 
nivåer av IL-6 och låg självskattad hälsa. Sambandet mellan IL-6 och låg självskattad hälsa 
hos män förmedlades inte av sjukdomsbeteende.  
I artikel III och IV undersöktes sambandet mellan självskattad hälsa, sjukdomsbeteende, 
astma-relaterad livskvalitet, inflammatoriska markörer och lungfunktion under ett års tid hos 
181 patienter med allergisk astma.  
Resultaten i artikel III visade att låg självskattad hälsa var kopplat till höga nivåer av IgE-
antikroppar mot säsongsbundna allergen (pollen från björk, timotej och gråbo) och mat-
allergen. Dock fanns ingen koppling till totalt IgE eller andra inflammatoriska markörer som 
EDN och ECP eller fraktionen utandad kvävemonoxid (FENO). När vi tittade på förändringen 
över tid kunde vi se att en ökning under året av perent IgE (allergen från hund, katt, häst och 
mögel) gav en försämring av den självskattade hälsan samt att en ökning av 
sjukdomsbeteende gav en sämre självskattad hälsa. Dessa fynd visade på sjukdomsbeteendets 
roll för hur man skattar sin hälsa och visade också att självskattad hälsa och 
sjukdomsbeteende samvarierar under en ett-års period hos patienter med allergisk astma.  
I artikel IV fann vi att ökat sjukdomsbeteende var kopplat till lägre astma-relaterad 
livskvalitet. Hos män kunde vi se ett u-format samband där både låga och höga nivåer av 
cytokinen IL-6 var kopplade till ökat sjukdomsbeteende. Dessutom var dålig lungfunktion 
kopplat till låg självskattad hälsa. När vi tittade på förändringarna över tid kunde vi se att en 
förbättring under året av den astma-relaterade livskvaliten också gav en förbättrad 
självskattad hälsa. Hos män såg vi att en förbättring i lungfunktionen var kopplad till en 
ökning av IL-6, bättre självskattad hälsa och bättre astma-relaterad livskvalitet.  
Sammanfattningsvis har denna avhandling gett ny kunskap om sjukdomsbeteendets roll i 
förhållande till subjektiv hälsouppfattning och inflammation. I avhandlingsarbetet ingick att 
utveckla och validera SicknessQ-skalan som mäter sjukdomsbeteende. Sjukdomsbeteende 
och astma-relaterad livskvalitet (hos patienter med astma) har betydelse för hur man skattar 
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sin hälsa. Sambanden mellan inflammatoriska markörer och självskattad hälsa, liksom 
betydelsen av IgE för den subjektiva hälsoupplevelsen vid IgE-relaterade ohälsotillstånd, 
behöver studeras mer i fortsatta forskningsstudier. Det viktigaste fyndet i denna avhandling 
var att sjukdomsbeteende och astmarelaterad livskvalitet visade sig vara viktiga faktorer för 
hur man skattar sin hälsa och att dessa samvarierar under en ett-års period hos patienter med 
allergisk astma. 
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